Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Eng, C; Dasari, A; Lonardi, S; Garcia-Carbonero, R; Elez, E; Yoshino, T; Sobrero, A; Yao, JM; Garcia-Alfonso, P; Kocsis, J; Gracian, AC; Sartore-Bianchi, A; Satoh, T; Randrian, V; Tomasek, J; Chong, GF; Yang, Z; Guevara, F; Schelman, W; Pallai, R; Tabernero, J.

Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer: safety analysis of FRESCO-2

ONCOLOGIST. 2025; 30(3): Nº de citas: 7 [doi:10.1093/oncolo/oyae360]

Hecht, JR; Oberoi, A; Cabanas, EG; Chon, HJ; Digklia, A; Rottey, S; Jimenez, MM; Chaney, M; Hippenmeyer, J; Lawrence, T; Liu, KT; Hamidi, A; Chesney, J.

Phase Ib/II trial of talimogene laherparepvec alone and with pembrolizumab in advanced solid tumors with liver metastases and hepatocellular carcinoma

ONCOLOGIST. 2025; 30(3): Nº de citas: 7 [doi:10.1093/oncolo/oyae203]

Mukhtar, RA; Gottipati, S; Yau, C; López-Tarruella, S; Earl, H; Hayward, L; Hiller, L; Osdoit, M; van der Noordaa, M; de Croze, D; Hamy, AS; Lae, M; Reyal, F; Sonke, GS; Steenbruggen, TG; van Seijen, M; Wesseling, J; Martín, M; del Monte-Millán, M; Boughey, JC; Goetz, MP; Hoskin, T; Valero, V; Edge, SB; Abraham, JE; Bartlett, JMS; Caldas, C; Dunn, J; Provenzano, E; Sammut, SJ; Thomas, JS; Graham, A; Hall, P; Mackintosh, L; Fan, F; Godwin, AK; Schwensen, K; Sharma, P; Demichele, AM; Cole, K; Pusztai, L; Kim, MO; van 't Veer, L; Cameron, D; Esserman, LJ; Symmans, WF.

A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer

npj Breast Cancer. 2025; 11(1): Nº de citas: 4 [doi:10.1038/s41523-025-00720-3]

Denkert C; Rachakonda S; Karn T; Weber K; Martin M; Marmé F; Untch M; Bonnefoi H; Kim SB; Seiler S; Bear HD; Witkiewicz AK; Im SA; DeMichele A; Pehl A; Van't Veer L; McCarthy N; Stiewe T; Jank P; Gelmon KA; García-Sáenz JA; Westhoff CC; Kelly CM; Reimer T; Felder B; Olivé MM; Knudsen ES; Turner N; Rojo F; Schmitt WD; Fasching PA; Teply-Szymanski J; Zhang Z; Toi M; Rugo HS; Gnant M; Makris A; Holtschmidt J; Nekljudova V; Loibl S.

Dynamics of molecular heterogeneity in high-risk luminal breast cancer-From intrinsic to adaptive subtyping.

CANCER CELL. 2025; 43(2): Nº de citas: 16 [doi:10.1016/j.ccell.2025.01.002]

Peña-Enríquez, R; Bermejo, B; Pollán, M; Díaz-Chacón, A; Gilarranz, YJ; Lorenzo, JJP; Aramburo, AF; de Ibargüen, BCS; Bertrán, AS; Galve-Calvo, E; Jiménez-Arranz, A; Fernández, Y; Pérez, ME; de la Cruz, S; Anton-Torres, A; Moreno, F; Vidal-Losada, MJ; López-Ceballos, MH; Blancas, I; Echarri, MJ; Rincón, R; Caballero, R; Guerrero-Zotano, A; Guil-Luna, S; de la Haba-Rodríguez, J.

Molecular characterization of pregnancy-associated breast cancer and insights on timing from GEICAM-EMBARCAM study

npj Breast Cancer. 2025; 11(1): Nº de citas: 8 [doi:10.1038/s41523-025-00718-x]

Serrano, C; Arregui, M; Carrasco, I; Hindi, N; Martínez-Trufero, J; Martínez-García, J; Molina, A; Paisán, A; Sánchez, R; Sala, MA.

SEOM-GEIS Spanish clinical guidelines for the management of soft-tissue sarcomas (2024)

Clinical & Translational Oncology. 2025; 27(4): 1460-1471 [doi:10.1007/s12094-024-03842-5]

Kandolf, L; Ascierto, PA; Bastholt, L; Gavrilova, I; Haanen, J; Hauschild, A; Herceg, D; Hoeller, C; Suljevic, AJ; Kessels, J; Krajsova, I; Kukushkina, M; Lallas, A; Lorigan, P; Mangana, J; Marquez-Rodas, I; Mazilu, L; Mohr, P; Bylaite-Bucinskiene, M; Ocvirk, J; Olah, J; Putnik, K; Rutkowski, P; Saiag, P; Samolyenko, I; Schwarze, JK; Stojkovski, I; Saric, NC; Vieira, R; Weichenthal, M; Garbe, C.

An update on access to novel treatment for metastatic melanoma in Europe - A 2024 survey of the European melanoma registry and the European association of dermato-oncology

EUROPEAN JOURNAL OF CANCER. 2025; 216: Nº de citas: 4 [doi:10.1016/j.ejca.2024.115124]

Lynce, F; Martinez-Sáez, O; Walbaum, B; Brasó-Maristany, F; Waks, AG; Villagrasa, P; Javierre, GV; Sanfeliu, E; Galvan, P; Paré, L; Anderson, LM; Perou, CM; Parker, JS; Vivancos, A; Dilullo, MK; Pernas, S; Winer, EP; Overmoyer, B; Mittendorf, EA; Bueno-Muiño, C; Martín, M; Prat, A; Tolaney, SM.

HER2DX in HER2-positive inflammatory breast cancer: correlative insights and comparative analysis with noninflammatory breast cancers5

ESMO Open. 2025; 10(2): Nº de citas: 5 [doi:10.1016/j.esmoop.2024.104100]

Martin-Liberal, J; Márquez-Rodas, I; Cerezuela-Fuentes, P; Soria, A; Garicano, F; Medina, J; Galindo, RG; Oramas, J; Manzano, JL; Delgado, M; Valdivia, J; Sanchez, P.

Challenges and perspectives in the management of BRAF-mutated metastatic melanoma: Systemic treatment sequencing and brain metastases

CANCER TREATMENT REVIEWS. 2025; 133: Nº de citas: 4 [doi:10.1016/j.ctrv.2025.102886]

Martín, M; Stecklein, SR; Gluz, O; Villacampa, G; Monte-Millán, M; Nitz, U; Cobo, S; Christgen, M; Brasó-Maristany, F; Alvarez, EL; Echavarría, I; Conte, B; Kuemmel, S; Bueno-Muiño, C; Jerez, Y; Kates, R; Cebollero, M; Kolberg-Liedtke, C; Bueno, O; García-Saenz, JA; Moreno, F; Grischke, EM; Forstbauer, H; Braun, M; Warm, M; Hackmann, J; Uleer, C; Aktas, B; Schumacher, C; Wuerstleins, R; Graeser, M; zu Eulenburg, C; Kreipe, HH; Gómez, H; Massarrah, T; Herrero, B; Paré, L; Bohn, U; López-Tarruella, S; Vivanco, A; Sanfeliu, E; Parker, JS; Perou, CM; Villagrasa, P; Prat, A; Sharma, P; Harbeck, N.

TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy

ANNALS OF ONCOLOGY. 2025; 36(2): 158-171 Nº de citas: 17 [doi:10.1016/j.annonc.2024.10.012]

Hortobagyi, GN; Lacko, A; Sohn, J; Cruz, F; Borrego, MR; Manikhas, A; Park, YH; Stroyakovskiy, D; Hurvitz, S; Barrios, C; Untch, M; Moroose, R; Yardley, DA; Visco, F; Chia, S; Huang, CS; Fasching, PA; Parnizari, F; Crown, J; Zarate, JP; Bardia, A; Loi, S; Li, Z; Martin, M; Xu, B; Im, SA; Waters, S; Chakravartty, A; Slamon, D.

A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial

ANNALS OF ONCOLOGY. 2025; 36(2): 149-157 Nº de citas: 80 [doi:10.1016/j.annonc.2024.10.015]

Demichele, A; Dueck, AC; Hlauschek, D; Martin, M; Burstein, H; Pfeiler, G; Zdenkowski, N; Wolff, A; Bellet-Ezquerra, M; Winer, E; Balic, M; Miller, K; Colleoni, M; Lake, D; Rubovsky, G; Cameron, D; Balko, J; Singer, CF; Nowecki, Z; Iwata, H; Wolmark, N; Parraga, KA; Rugo, H; Steger, GG; Traina, T; Werutsky, G; Czajkowska, D; Metzger, O; El-Abed, S; Theall, KP; Lu, RD; O'Brien, P; Fesl, C; Mayer, E; Gnant, M.

Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13])

BREAST CANCER RESEARCH. 2025; 27(1): Nº de citas: 2 [doi:10.1186/s13058-024-01941-3]

Amaral, T; Nanz, L; Higuita, LMS; Ascierto, P; Berking, C; Couselo, EM; Donia, M; Dummer, R; Gutzmer, R; Haushild, A; Jalving, M; Lee, RBC; Lorigan, P; Marquez-Rodas, I; Michelin, O; Nathan, P; Robert, C; Schadendorf, D; Sobczuk, P; Flatz, L; Leiter, U; Garbe, C.

A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature research

EUROPEAN JOURNAL OF CANCER. 2025; 215: Nº de citas: 4 [doi:10.1016/j.ejca.2024.115160]

Lenz, HJ; Liu, TS; Chen, EY; Horváth, Z; Bondarenko, I; Danielewicz, I; Ghidini, M; García-Alfonso, P; Jones, R; Aapro, M; Zhang, YQ; Wang, JF; Wang, WY; Adeleye, J; Beelen, A; Hubbard, J.

Trilaciclib prior to FOLFOXIRI/bevacizumab for patients with untreated metastatic colorectal cancer: phase 3 PRESERVE 1 trial

JNCI Cancer Spectrum. 2025; 9(1): Nº de citas: 5 [doi:10.1093/jncics/pkae116]

Wolchok, JD; Chiarion-Sileni, V; Rutkowski, P; Cowey, CL; Schadendorf, D; Wagstaff, J; Queirolo, P; Dummer, R; Butler, MO; Hill, AG; Postow, MA; Gaudy-Marqueste, C; Medina, T; Lao, CD; Walker, J; Márquez-Rodas, I; Haanen, JBAG; Guidoboni, M; Maio, M; Schöffski, P; Carlino, MS; Sandhu, S; Lebbé, C; Ascierto, PA; Long, GV; Ritchings, C; Nassar, A; Askelson, M; Benito, MP; Wang, WJ; Hodi, FS; Larkin, J.

Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma

NEW ENGLAND JOURNAL OF MEDICINE. 2025; 392(1): Nº de citas: 330 [doi:10.1056/NEJMoa2407417]

Robert C; Long GV; Larkin J; Wolchok JD; Hassel JC; Schadendorf D; Hodi FS; Lebbé C; Grob JJ; Hyngstrom JR; Wagstaff J; Chesney J; Butler MO; Bechter O; Márquez-Rodas I; Pavlick AC; Durani P; Pe Benito M; Wang P; Postow MA; Ascierto PA.

Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients.

EUROPEAN JOURNAL OF CANCER. 2025; 214: 115119-115119 Nº de citas: 11 [doi:10.1016/j.ejca.2024.115119]

Calles, A; Alonso, M; Martín-Martorell, P; Gómez, A; de Castro, J; Martínez-Aguillo, M; Estival, A; Mosquera, J; Martínez-Banaclocha, N; Majem, M; Reyes, R; Azkona, E; Ortega, AL; Aguin, S; Santos, A; Aguilar, A; Cucurull, M; Blasco, A; Calvo, V; Isla, D; Nadal, E; Aguado, C; Sais, E; Juan-Vidal, O; Diz-Taín, M; Taus, A; Villanueva, N; Bayona, C; Amenedo, M; Mielgo, X; Arriola, E; Baena, J.

Efficacy and safety of lorlatinib in patients with ALK-and ROS1-rearranged metastatic non-small cell lung cancer treated within the compassionate use program in Spain

Cancer Treatment and Research Communications. 2025; 43: Nº de citas: 2 [doi:10.1016/j.ctarc.2025.100905]

Isla, D; Alvarez, R; Arnal, M; Arriola, E; Azkarate, A; Azkona, E; García-Campelo, R; Garrido, P; Nadal, E; Ortega, AL; Carcedo, D; Crespo, M; Lavara, J; Córcoles, F; Bernabé, R.

Detection of genomic alterations in liquid biopsies from patients with non-small cell lung cancer using FoundationOne Liquid CDx: a cost-effectiveness analysis

JOURNAL OF MEDICAL ECONOMICS. 2024; 27(1): 1379-1387 Nº de citas: 4 [doi:10.1080/13696998.2024.2413289]